Sarolaner

Sarolaner (PF-6450567) is an orally active and broad-spectrum ectoparasiticide . Sarolaner is an isoxazoline compound which shows efficacy against fleas and ticks on dogs, with a LC 80 value of 0.3 μg/mL against C. felis and a LC 100 value of 0.003 μg/mL against O. turicata In Vitro Sarolaner (450 nM-1 mM; 5 min) inhibits CfRDL-A285 and CfRDL-S285 receptors with γ-Aminobutyric acid (GABA)-induced currents. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: CHO-K1 cell lines Concentration: 450 nM-1 mM Incubation Time: 5 min Result: Inhibited GABA-elicited currents at both susceptible (CfRDL-A285) and resistant (CfRDL-S285) flea GABACls with EC 50 s of 135 and 136 nM, respectively. In Vivo Sarolaner (2.5 mg/kg; p.o. once) shows 100% efficacious against R. sanguineus and D. reticulatus . Sarolaner (1.25- 5 mg/kg; p.o. once) effectively against I. ricinus . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Dog infested with R. sanguineus and D. reticulatus Dosage: 2.5 mg/kg Administration: Oral gavage; 2.5 mg/kg once Result: Exibited 100% efficacy against R. sanguineus at 48 hours after treatment and also exhibited 98.0% efficacy against D. reticulatus . Animal Model: Dog infested with I. ricinus Dosage: 1.25, 2.5 and 5 mg/kg Administration: Oral gavage; 1.25, 2.5 and 5 mg/kg once Result: Exibited 100% efficacy against I. ricinus at all doses until 7 days, and provided over 99.3% reduction against subsequent re-infestations until 57 days at dose of 5.0 and 2.5 mg/kg. Form:Solid IC50& Target:LC80: 0.3μg/mL ( C. felis ), LC100: 0.003 μg/mL ( O. turicata ), IC50: 135 nM (CfRDL-A285), 136 nM (CfRDL-S285)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet